International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) - Summary - MDSpire

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

  • By

  • María-Victoria Mateos

  • Shaji Kumar

  • Meletios A. Dimopoulos

  • Verónica González-Calle

  • Efstathios Kastritis

  • Roman Hajek

  • Carlos Fernández De Larrea

  • Gareth J. Morgan

  • Giampaolo Merlini

  • Hartmut Goldschmidt

  • Catarina Geraldes

  • Alessandro Gozzetti

  • Charalampia Kyriakou

  • Laurent Garderet

  • Markus Hansson

  • Elena Zamagni

  • Dorotea Fantl

  • Xavier Leleu

  • Byung-Su Kim

  • Graça Esteves

  • Heinz Ludwig

  • Saad Usmani

  • Chang-Ki Min

  • Ming Qi

  • Jon Ukropec

  • Brendan M. Weiss

  • S. Vincent Rajkumar

  • Brian G. M. Durie

  • Jesús San-Miguel

  • October 16, 2020

  • 0 min

Share

Objective:

To develop a risk stratification model for identifying SMM patients at high risk of progression to multiple myeloma (MM) within 2 years, specifically using the 2014 IMWG criteria.

Key Findings:
  • Identified significant factors predicting progression to MM: M-protein (>2 g/dL), BMPCs infiltration (>20%), and involved/uninvolved sFLC ratio (>20), which can guide clinical decisions.
  • Developed a risk score for individualized 2-year progression risk assessment, enhancing patient management.
Interpretation:

The study provides a comprehensive risk stratification model that can help in predicting progression in SMM patients, addressing the heterogeneity in previous models and offering a practical tool for clinicians.

Limitations:
  • Retrospective design may introduce bias, potentially affecting the generalizability of the findings.
  • Data collected from multiple sites may vary in quality, which could influence the reliability of the results.
Conclusion:

The new risk stratification model enhances the ability to identify high-risk SMM patients and supports individualized treatment approaches.

Original Source(s)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

  • by María-Victoria Mateos, Shaji Kumar, Meletios A. Dimopoulos, Verónica González-Calle, Efstathios Kastritis, Roman Hajek, Carlos Fernández De Larrea, Gareth J. Morgan, Giampaolo Merlini, Hartmut Goldschmidt, Catarina Geraldes, Alessandro Gozzetti, Charalampia Kyriakou, Laurent Garderet, Markus Hansson, Elena Zamagni, Dorotea Fantl, Xavier Leleu, Byung-Su Kim, Graça Esteves, Heinz Ludwig, Saad Usmani, Chang-Ki Min, Ming Qi, Jon Ukropec, Brendan M. Weiss, S. Vincent Rajkumar, Brian G. M. Durie, Jesús San-Miguel

  • October 16, 2020

Related Content

Not all plasma cells are made equal: well-hidden layers of heterogeneity

Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min